Arimidex is the brand name for the medication anastrozole. It is a prescription medication that belongs to a class of drugs called aromatase inhibitors. Arimidex is primarily used in the treatment of breast cancer in postmenopausal women. Here is some information about Arimidex:


Treatment of Breast Cancer

Arimidex (anastrozole) is primarily prescribed for the treatment of hormone receptor-positive breast cancer in postmenopausal women. This type of breast cancer grows in response to the hormone estrogen. Arimidex works by reducing the production of estrogen in the body, thereby slowing down the growth of the cancer cells.

Usage and Dosage

Arimidex is available in tablet form and is taken orally. The dosage and duration of treatment will depend on various factors, including the stage and characteristics of the breast cancer, as well as individual patient factors. It is important to follow the instructions provided by a healthcare professional and take Arimidex exactly as prescribed.

Effectiveness and Monitoring

Arimidex has been shown to be effective in reducing the risk of cancer recurrence and improving overall survival rates in postmenopausal women with hormone receptor-positive breast cancer. Regular follow-up appointments and medical monitoring are important to assess the response to treatment and manage any potential side effects.

Precautions and Potential Side Effects

Arimidex may cause certain side effects, which can vary from person to person. Common side effects may include hot flashes, joint pain, nausea, fatigue, and headache. More serious side effects, although rare, can include bone loss or fractures, increased cholesterol levels, and liver problems. It is important to report any unusual or severe side effects to a healthcare professional.

Arimidex may interact with other medications, so it is important to inform your healthcare professional about all the medications you are currently taking.

Consultation with Healthcare Professional

Arimidex is a prescription medication, and its use should be supervised by a healthcare professional, typically an oncologist or breast cancer specialist. It is important to consult with a healthcare professional to determine the appropriate treatment plan, assess the potential benefits and risks of Arimidex, and discuss any concerns or questions you may have.

WARNING: Please consult with a healthcare professional or doctor for personalized advice and guidance regarding the use of Arimidex or any other medication for the treatment of breast cancer. They will be able to provide specific instructions based on your medical history and individual needs.


  1. Jump up to:a b c d e f “Anastrozole”.
  2. Jump up to:a b c d e f g h i j k l m Lønning P (2003). “Clinical pharmacokinetics of aromatase inhibitors and inactivators”. Clinical Pharmacokinetics42 (7): 619–631. doi:10.2165/00003088-200342070-00002PMID 12844324S2CID 9585901.
  3. Jump up to:a b c d e f g h i j k l m n o p q r s t Lønning P, Pfister C, Martoni A, Zamagni C (August 2003). “Pharmacokinetics of third-generation aromatase inhibitors”. Seminars in Oncology30 (4 Suppl 14): 23–32. doi:10.1016/S0093-7754(03)00305-1PMID 14513434.
  4. Jump up to:a b c d e f g h i j k l m n o p q Sanford M, Plosker GL (2008). “Anastrozole: a review of its use in postmenopausal women with early-stage breast cancer”. Drugs68 (9): 1319–1340. doi:10.2165/00003495-200868090-00007PMID 18547136.
  5. ^ “anastrozole”Chemical Entities of Biological Interest (ChEBI). European Molecular Biology Laboratory. Archived from the original on 2011-09-22. Retrieved 2011-08-14.
  6. Jump up to:a b c d e f g h i j k l “Highlights of Prescribing Information Anastrozole” (PDF). FDA. Retrieved 31 July 2019.
  7. Jump up to:a b c d e f g h i j k “Anastrozole”. The American Society of Health-System Pharmacists. Archived from the original on 21 December 2016. Retrieved 8 December 2016.
  8. Jump up to:a b Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 516. ISBN 9783527607495Archived from the original on 2016-12-20.
  9. Jump up to:a b Dukes M (1997). “The relevance of preclinical models to the treatment of postmenopausal breast cancer”. Oncology54 (2): 6–10. doi:10.1159/000227748PMID 9394853.
  10. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  11. ^ “The Top 300 of 2020”ClinCalc. Retrieved 7 October 2022.
  12. ^ “Anastrozole – Drug Usage Statistics”ClinCalc. Retrieved 7 October 2022.
  13. Jump up to:a b c Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al. (2005). “Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer”. Lancet365 (9453): 60–62. doi:10.1016/S0140-6736(04)17666-6PMID 15639680S2CID 8350282[non-primary source needed]
  14. ^ “Casodex® (bicalutamide) Tablets” (PDF). FDA. Archived (PDF) from the original on 30 July 2019.
  15. ^ Schoelwer M, Eugster EA (2015). “Treatment of Peripheral Precocious Puberty”. Puberty from Bench to Clinic. Endocrine Development. Vol. 29. pp. 230–9. doi:10.1159/000438895ISBN 978-3-318-02788-4PMC 5345994PMID 26680582.
  16. ^ Zacharin M (May 2019). “Disorders of Puberty: Pharmacotherapeutic Strategies for Management”. Handbook of Experimental Pharmacology261: 507–538. doi:10.1007/164_2019_208ISBN 978-3-030-50493-9PMID 31144045S2CID 169040406.
  17. ^ Kliegman RM, Stanton B, St Geme J, Schor NF (17 April 2015). Nelson Textbook of Pediatrics. Elsevier Health Sciences. pp. 2661–. ISBN 978-0-323-26352-8.
  18. ^ Neyman A, Eugster EA (December 2017). “Treatment of Girls and Boys with McCune-Albright Syndrome with Precocious Puberty – Update 2017”Pediatric Endocrinology Reviews15 (2): 136–141. doi:10.17458/per.vol15.2017.nau.treatmentgirlsboysPMC 5808444PMID 29292624.
  19. ^ Haddad NG, Eugster EA (2012). “Peripheral Precocious Puberty: Interventions to Improve Growth”. Handbook of Growth and Growth Monitoring in Health and Disease. pp. 1199–1212. doi:10.1007/978-1-4419-1795-9_71ISBN 978-1-4419-1794-2.
  20. ^ Haddad NG, Eugster EA (June 2019). “Peripheral precocious puberty including congenital adrenal hyperplasia: causes, consequences, management and outcomes”. Best Practice & Research. Clinical Endocrinology & Metabolism33 (3): 101273. doi:10.1016/j.beem.2019.04.007hdl:1805/19111PMID 31027974S2CID 135410503.
  21. ^ Misra M, Radovick S (2018). “Precocious Puberty”. Pediatric Endocrinology. pp. 589–615. doi:10.1007/978-3-319-73782-9_26ISBN 978-3-319-73781-2.
  22. ^ Mauras N (October 2011). “Strategies for maximizing growth in puberty in children with short stature”. Pediatric Clinics of North America58 (5): 1167–79, x. doi:10.1016/j.pcl.2011.07.007PMID 21981954.
  23. ^ Fuqua JS (June 2013). “Treatment and outcomes of precocious puberty: an update”The Journal of Clinical Endocrinology and Metabolism98 (6): 2198–2207. doi:10.1210/jc.2013-1024PMID 23515450.
  24. Jump up to:a b White R, Bradnam V (11 March 2015). Handbook of Drug Administration via Enteral Feeding Tubes, 3rd edition. Pharmaceutical Press. pp. 108–. ISBN 978-0-85711-162-3.
  25. ^ Simpson ER (September 2003). “Sources of estrogen and their importance”. The Journal of Steroid Biochemistry and Molecular Biology86 (3–5): 225–230. doi:10.1016/S0960-0760(03)00360-1PMID 14623515S2CID 11210435.
  26. ^ Costa R, Carneiro BA, Wainwright DA, Santa-Maria CA, Kumthekar P, Chae YK, et al. (January 2017). “Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives”Annals of Oncology28 (1): 44–56. doi:10.1093/annonc/mdw532PMC 7360139PMID 28177431.
  27. ^ Russell N, Cheung A, Grossmann M (August 2017). “Estradiol for the mitigation of adverse effects of androgen deprivation therapy”Endocrine-Related Cancer24 (8): R297–R313. doi:10.1530/ERC-17-0153PMID 28667081.
  28. Jump up to:a b Miyajima M, Kusuhara H, Takahashi K, Takashima T, Hosoya T, Watanabe Y, Sugiyama Y (September 2013). “Investigation of the effect of active efflux at the blood-brain barrier on the distribution of nonsteroidal aromatase inhibitors in the central nervous system”. Journal of Pharmaceutical Sciences102 (9): 3309–3319. doi:10.1002/jps.23600PMID 23712697.
  29. ^ Thurston DE (22 November 2006). Chemistry and Pharmacology of Anticancer Drugs. CRC Press. pp. 136–. ISBN 978-1-4200-0890-6.
  30. ^ Roy, Kunal (28 February 2015). Quantitative Structure-Activity Relationships in Drug Design, Predictive Toxicology, and Risk Assessment. IGI Global. pp. 437–. ISBN 978-1-4666-8137-8.
  31. ^ Smith DA, Allerton C, Kalgutkar AS, van de Waterbeemd H, Walker DK (13 September 2012). Pharmacokinetics and Metabolism in Drug Design. John Wiley & Sons. pp. 197–. ISBN 978-3-527-64529-9.
  32. ^ Environmental Health Perspectives: Supplements. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Environmental Health Sciences. 1993. pp. 256–260.
  33. ^ Fagerlund A, Cormio L, Palangi L, Lewin R, Santanelli di Pompeo F, Elander A, Selvaggi G (2015). “Gynecomastia in Patients with Prostate Cancer: A Systematic Review”PLOS ONE10 (8): e0136094. Bibcode:2015PLoSO..1036094Fdoi:10.1371/journal.pone.0136094PMC 4550398PMID 26308532.
  34. ^ Bedognetti D, Rubagotti A, Zoppoli G, Boccardo F (2010). “Gynaecomastia: the anastrozole paradox”. Journal of Pediatric Endocrinology & Metabolism23 (1–2): 205–206. doi:10.1515/JPEM.2010.23.1-2.205PMID 20432826S2CID 41999854.
  35. ^ “Anastrozole – AstraZeneca”Adis Insight.
  36. ^ “Anastrozole/levonorgestrel intravaginal ring – Bayer HealthCare”Adis Insight.
  37. Jump up to:a b Serefoglu EC, Gokce A, Hellstrom WJ, Guay AT (2013). “Alternate Therapies for Testosterone Replacement”. Androgen Deficiency and Testosterone Replacement. pp. 141–147. doi:10.1007/978-1-62703-179-0_11ISBN 978-1-62703-178-3.
  38. ^ Khera M, Adaikan G, Buvat J, Carrier S, El-Meliegy A, Hatzimouratidis K, et al. (December 2016). “Diagnosis and Treatment of Testosterone Deficiency: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015)”. The Journal of Sexual Medicine13 (12): 1787–1804. doi:10.1016/j.jsxm.2016.10.009PMID 27914560.